Catalog No.
DHB95803
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
IL2-RA, IL-2R subunit alpha, TAC antigen, IL-2-RA, p55, IL2RA, IL-2 receptor subunit alpha, Interleukin-2 receptor subunit alpha, CD25
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P01589
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
ADCT-301(unconjugated), HuMax-TAC-ADC, CAS: 921618-45-3
Clone ID
Camidanlumab
Targeting CD25+ lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents., PMID:39080847
The optimal management of relapsed and refractory Hodgkin lymphoma: post-brentuximab and checkpoint inhibitor failure., PMID:38066906
What's new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?, PMID:37902460
Development of recalcitrant cutaneous eruptions in patients with relapsed/refractory Hodgkin's lymphoma undergoing treatment with camidanlumab tesirine., PMID:36800311
Immunotherapy for Hodgkin lymphoma: From monoclonal antibodies to chimeric antigen receptor T-cell therapy., PMID:36702422
Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma., PMID:36333464
Exposure-response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma., PMID:36333463
CD25-targeted antibody-drug conjugate camidanlumab tesirine for relapsed or refractory classical Hodgkin lymphoma., PMID:36074313
Acute Interstitial Nephritis Triggered by a Novel Anti-CD25 Antibody-Drug Conjugate, Camidanlumab Tesirine., PMID:35257078
Current salvage therapies in Hodgkin lymphoma., PMID:35037568
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study., PMID:34048682
Future directions in Hodgkin lymphoma: checkpoint inhibitors and beyond., PMID:33602008
A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine., PMID:33492560
CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity., PMID:32912922
The Role of Specific ATP-Binding Cassette Transporters in the Acquired Resistance to Pyrrolobenzodiazepine Dimer-Containing Antibody-Drug Conjugates., PMID:32669316
Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy., PMID:32543981
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study., PMID:32521310
For research use only. Not for human or drug use.
